877399-74-1

基本信息
克唑替尼杂质B
克唑替尼杂质2
环唑替尼杂质1
克里唑替尼中间体
4-硼酸频那醇酯
克里唑替尼硼酸酯片段
1-(1-BOC-4哌啶)吡唑-4-硼酸频哪醇酯
1-(N-BOC-4-哌啶)-4-吡唑硼酸频哪醇酯
1-(N-BOC-哌啶4基)吡唑-4-硼酸频哪醇酯
Crizotinib intermediates 2
InterMediate Ⅱ of Crizotinib
Borate fragment of crizotinib
1-Piperidinecarboxylic acid, 4
tert-Butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-
1-(1-Boc-4-piperidyl)pyrazole-4-boronic acid pinacol ester
1-(4-N-Boc-piperidine)pyrazole-4-boronic acid pinacol ester
1-(1-Boc-piperidin-4-yl)-pyrazole-4-boronic acid picol ester
1-(1-Boc-piperidin-4-yl)-pyrazole-4-boronic acid pinacol ester
物理化学性质
制备方法

877399-73-0

73183-34-3
![4-[4-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)-1H-吡唑-1-基]哌啶-1-甲酸叔丁酯](/CAS/GIF/877399-74-1.gif)
877399-74-1
向1-Boc-4-(4-碘-1H-吡唑-1-基)哌啶(1.00g,2.650mmol)的二甲基亚砜(DMSO,11mL)溶液中依次加入联硼酸频那醇酯(942.5mg,3.710mmol)和乙酸钾(CH3COOK,1.04g,10.60mmol)。将反应混合物进行脱气处理,并用氮气(N2)置换三次,随后加入二氯双(三苯基膦)钯(Pd(PPh3)2Cl2,93.0mg,0.130mmol)。将所得混合物在80℃下搅拌反应2小时,反应完成后冷却至室温,通过硅藻土垫过滤。滤液用饱和盐水(100mL×3)洗涤,无水硫酸钠(Na2SO4)干燥,减压浓缩。残余物通过硅胶柱色谱法(石油醚/乙酸乙酯,v/v=5/1)纯化,得到4-(4-硼酸频哪醇酯基-1H-吡唑-1-基)哌啶-1-羧酸叔丁酯,为白色固体(878.6mg,收率87.9%)。质谱(ESI,正离子模式)m/z:378.0([M+H]+)。
参考文献:
[1] Patent: WO2014/193647, 2014, A2. Location in patent: Paragraph 0185
[2] Patent: CN104119331, 2018, B. Location in patent: Paragraph 0382; 0390; 0391
[3] Patent: WO2010/68292, 2010, A1. Location in patent: Page/Page column 85-86
[4] Patent: WO2014/89280, 2014, A1. Location in patent: Page/Page column 50
[5] Patent: CN103833753, 2017, B. Location in patent: Paragraph 0352; 0358; 0359
常见问题列表
4-[4-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)-1H-吡唑-1-基]哌啶-1-甲酸叔丁酯主要作为医药中间体。
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2025/05/22 | XW0287739974105 | 4-[4-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)-1H-吡唑-1-基]哌啶-1-甲酸叔丁酯 | 877399-74-1 | 100G | 1060元 |
2025/05/22 | XW0287739974104 | 4-[4-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)-1H-吡唑-1-基]哌啶-1-甲酸叔丁酯 | 877399-74-1 | 25G | 266元 |
2025/05/22 | B5002 | 4-[4-(4,4,5,5-四甲基-1,3,2-二氧硼戊环-2-基)吡唑-1-基]哌啶-1-甲酸叔丁酯 tert-Butyl 4-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]piperidine-1-carboxylate | 877399-74-1 | 1g | 90元 |